DASB C-11
Impulse Control Disorders
Hospices Civils de LyonSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Impulse Control Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
carbidopa Sandoz | Phase 4 | BB |
LEVODOPA University Hospital Bispebjerg and Frederiksberg | Phase 4 | BB |
Naltrexone University of Pennsylvania | Phase 4 | BB |
Clonidine Hospices Civils de Lyon | Phase 2 | B |
Naratriptan UMC Utrecht | Phase 4 | B |
View all 9 →
Same molecule, other indications
DASB C-11 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →